Will we have a treatment for Alzheimer's disease that halts the progression of the disease by 2035?
Salute e medicinaOne-Off8aManifold MarketsSenza KYCDati di risoluzione verificatiBen calibratoPrevisione della comunità attualeNo 70%
Previsori
8
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 14 ore fa
Obsoleto13 nov 24, 12:49 UTC1 gen 35, 22:59 UTC
Trend
Regole
Alzheimer's disease is thought to be caused by the abnormal build-up of proteins in and around brain cells, namely beta-amyloid plaques and tau tangles.
- Currently, there are two anti-amyloid treatments for early AD, Leqembi (lecanemab) and Kisunla (donanemab).
- They show a 27.1% [1] and 31.8% [2] reduction in disease progression compared to placebo over 18 months.
- Will we a treatment that shows a 90% reduction in disease progression over 18 months by 2035?
- The treatment must be FDA approved and the disease progression must be characterized by an approved rating like Clinical Dementia Rating – Sum of Boxes (CDR-SB) or Integrated Alzheimer’s Disease Rating Scale (iADRS).
- The treatment can be of any kind (small molecule, antibody, gene therapy), but must comparable in "curing" the disease rather than treating the symptoms.
